

Pharmacy Management Drug Policy

SUBJECT: Lantidra - (donislecel-jujn) POLICY NUMBER: PHARMACY-115 EFFECTIVE DATE: 05/2024 LAST REVIEW DATE: 06/12/2026		
<i>If the member's subscriber contract excludes coverage for a specific service or prescription drug, it is not covered under that contract. In such cases, medical or drug policy criteria are not applied. This drug policy applies to the following line/s of business:</i>		
Policy Application		
Category:	<input checked="" type="checkbox"/> Commercial Group (e.g., EPO, HMO, POS, PPO)	<input checked="" type="checkbox"/> Medicare Advantage
	<input checked="" type="checkbox"/> On Exchange Qualified Health Plans (QHP)	<input type="checkbox"/> Medicare Part D
	<input checked="" type="checkbox"/> Off Exchange Direct Pay	<input checked="" type="checkbox"/> Essential Plan (EP)
	<input checked="" type="checkbox"/> Medicaid & Health and Recovery Plans (MMC/HARP)	<input checked="" type="checkbox"/> Child Health Plus (CHP)
	<input type="checkbox"/> Federal Employee Program (FEP)	<input type="checkbox"/> Ancillary Services
	<input checked="" type="checkbox"/> Dual Eligible Special Needs Plan (D-SNP)	

DESCRIPTION:

In the United States, approximately 2 million Americans are diagnosed with type 1 diabetes, including roughly 304,000 children and adolescents. This accounts for 5-10% of diabetes cases.^{1,2} Type 1 diabetes is primarily caused by autoimmune destruction of insulin producing pancreatic β -cells. Children typically present with polyuria, polydipsia, and diabetic ketoacidosis (DKA)—which can be life-threatening. Adults tend to have more variable symptoms, but certain features may differentiate a diagnosis of type 1 diabetes such as: younger age (<35 years), lower body mass index BMI of < 25 kg/m², ketoacidosis, plasma glucose >360 mg/dL, and unintentional weight loss. Genetic and environmental factors (e.g., diet, viruses) also play a role in precipitating autoimmune β -cell damage in type 1 diabetes.² A defining feature of the disease is the presence of autoantibodies, specifically those that target glutamic acid decarboxylase, insulin, tyrosine phosphatases islet antigen 2 (IA-2), IA-2 β , and zinc transporter 8 (ZnT8).²

The absence of β -cell function requires intensive insulin replacement consisting of multiple daily injections or continuous subcutaneous insulin administered through a pump. According to the American Diabetes Association (ADA), continuous glucose monitoring (CGM) is recommended for adults with type 1 diabetes and automated insulin delivery systems should be considered.³ The overarching goal of insulin therapy in type 1 diabetes is a customized treatment approach to prevent DKA, minimize hypoglycemia, and achieve an individual's glycemic targets. For some individuals, hypoglycemia and hypoglycemia unawareness can be especially challenging when managing type 1 diabetes.³

Beyond insulin, surgical treatments for type 1 diabetes include pancreas and islet transplantation to replace β -cells. According to the 2021 ADA/European Association for the Study of Diabetes (EASD) consensus report, β -cell replacement may serve as a therapeutic option for individuals who experience severe metabolic complications including severe hypoglycemia and hypoglycemia unawareness.⁴ Whole pancreas transplant and pancreatic islet transplantation both require lifelong immunosuppression. The ADA/EASD suggests carefully considering the risks versus benefit of β -cell replacement because of the need for chronic immunosuppression. The consensus report does note that these approaches have not been compared to newer closed-loop technology, which could avoid immunosuppression altogether.⁴

Pharmacy Management Drug Policy

Lantidra-(donislecel-jujn)

On June 28, 2023, the Food and Drug Administration (FDA) approved Lantidra (donislecel-jujn), an allogenic pancreatic islet therapy, indicated for the treatment of adults with type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe hypoglycemia despite intensive diabetes management and education.⁵ Lifelong immunosuppression is required to maintain islet cell viability. Lantidra is manufactured from the deceased donor pancreatic cells and is administered via the hepatic portal vein as single infusion. A total of three infusion may be performed based on the patient's response.

Approval of Lantidra was based on two non-randomized single-arm, open-label studies involving a combined 30 participants (UIH-001 and UIH-002), all of whom received at least one islet infusion and a maximum of 3 infusions.⁵ A total of 11 participants received 1 infusion, 12 participants received 2 infusions, and 7 participants received 3 infusions. The primary efficacy analysis used a composite endpoint of an HbA1c \leq 6.5% and absence of severe hypoglycemic events (SHE) through one year after the subject's last transplant. This data was deemed uninterpretable according to the FDA based on substantial missing data and the enrolled population having met or nearly met the primary endpoint at baseline.⁶ Insulin independence was a primary endpoint in the UIH-001 trial and a pre-specified secondary endpoint in the UIH-002 trial. In all, 25 (83.3%) of 30 participants were able to achieve insulin independence for any duration 4 days to 12.9 years. For the 25 individuals who achieved insulin independence, 4 participants (13.3%) were insulin independent for less than 1 year, 12 participants (36.7%) for 1 to 5 years, and 9 participants (33.3%) for greater than 5 years.^{5,6}

From a safety perspective, 90% of individuals experienced a serious adverse reaction, with two deaths reported: one due to multi-organ failure with sepsis (1.6 years after first infusion) and the other from progressive confusion, global atrophy and micro-ischemic disease (9.7 years after first infusion).⁵ Immunosuppression related adverse reactions were common and included infections in 26 patients (87%) and malignancy in 11 patients (37%).⁵ Types of malignancies included skin cancer, breast cancer, thyroid cancer, and post-transplant lymphoproliferative disease. Anemia occurred in 24 participants, with 9 severe reactions (Hgb < 6.5 gm/dL) and 27 moderately severe reactions (<10-8 gm/dL).⁵ Procedural complications included one liver laceration, one intraabdominal hemorrhage and two perihepatic hematomata. Other common side effects included nausea, fatigue, diarrhea, abdominal pain, asthenia, and headache.⁵

Despite the FDA advisory committee vote in favor of approval (12 to 4, with 1 abstention), concerns were raised regarding the study design including patient selection, lack of control group comparing current standard of care therapies, and serious side effects reported.⁶ Additionally, the FDA Biologics License Application Clinical Review Memorandum cites "numerous protocol deviations across the studies that could impair the interpretation of both efficacy and safety data."⁶

POLICY:

Commercial/Essential/Medicaid criteria:

Based upon our criteria and assessment of the peer-reviewed evidence, the use of Lantidra (donislecel-jujn) has not been medically proven to be effective and, therefore, is considered **not medically necessary** for the treatment of adults with Type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe hypoglycemia despite intensive diabetes management and education. The justification for Lantidra (donislecel-jujn) to be considered not medically necessary is as follows:

- A. Based on our assessment of the peer-reviewed literature, there is inconclusive evidence that the drug has a definite positive effect on health outcomes.

Pharmacy Management Drug Policy

Lantidra-(donislecel-jujn)

- B. Based upon our assessment of the peer-reviewed medical literature, there is inconclusive evidence that the drug, over time, leads to improvement in health outcomes (e.g., the beneficial effects of the service outweigh any harmful effects).
- C. Based upon our assessment of peer-reviewed medical literature, there is inconclusive evidence that the drug is at least as effective in improving health outcomes as established services or technologies
- D. Based upon our assessment of peer-reviewed medical literature, there is inconclusive evidence that the drug provides improvement in health outcomes in standard conditions of medical practice, outside the clinical investigatory settings.

Refer to Corporate Medical Policy #11.01.03 Experimental or Investigational Services

Medicare criteria:

Medicare reviews are to follow the current National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) issued by CMS. The NCD for Islet Cell Transplantation in the Context of a Clinical Trial can be found at: [NCD - Islet Cell Transplantation in the Context of a Clinical Trial \(260.3.1\) \(cms.gov\)](#).

POLICY GUIDELINES:

1. Unless otherwise stated above within the criteria, approval time-period will be for 1 year.
2. Utilization Management are contract dependent. Refer to specific contract/benefit language for exclusions.
 - a. Coverage criteria may be dependent on the contract renewal date.
 - b. Coverage of drugs listed in this policy are contract dependent.
 - c. Not all contracts/benefits allow coverage of healthcare professional administered drugs as part of their pharmacy benefit
 - d. Not all contracts/benefits cover all medical infusible drugs.
3. Clinical documentation must be submitted for each request (initial and recertification [if applicable]) unless otherwise specified (e.g., provider attestation required). Supporting documentation includes, but is not limited to, progress notes documenting previous treatments and treatment history, diagnostic testing, laboratory test results, genetic testing or biomarker results, imaging and other objective or subjective measures of benefit.
4. Lantidra is administered through hepatic portal vein and will be considered for coverage under the medical benefit
5. See related policy: *Corporate Medical Policy # 7.02.01 Pancreas Transplant: (Pancreas Transplant Alone, Pancreas Transplant after Kidney Transplant, Simultaneous Pancreas Kidney Transplant): Islet Cell Transplant*
6. Due to limited safety and efficacy data, Lantidra is limited to a maximum of 3 lifetime infusions and must be administered in accordance with FDA-approved labeling.
7. This policy does not apply to Medicare Part D and D-SNP pharmacy benefits. The drugs in this policy may apply to all other lines of business including Medicare Advantage.
8. For members with Medicare Advantage, medications with a National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) will be covered pursuant to the criteria outlined by the NCD and/or LCD. NCDs/LCDs for applicable medications can be found on the CMS website at <https://www.cms.gov/medicare-coverage-database/search.aspx>. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS permits a Medicare Advantage Organization (MAO) to establish its own coverage determinations in accordance with 42 CFR § 422.101(b)(6). Indications that have not been

Pharmacy Management Drug Policy

Lantidra-(donislecel-jujn)

addressed by the applicable medication's LCD/NCD will be covered in accordance with criteria determined by the Health Plan. Step therapy requirements may be imposed in addition to LCD/NCD requirements.

9. All utilization management requirements outlined in this policy are compliant with applicable New York State insurance laws and regulations. Policies will be reviewed and updated as necessary to ensure ongoing compliance with all state and federally mandated coverage requirements.
10. Manufacturers may either discontinue participation in, or may not participate in, the Medicaid Drug Rebate Program (MDRP). Under New York State Medicaid requirements, physician-administered drugs must be produced by manufacturers that participate in the MDRP. Products made by manufacturers that do not participate in the MDRP will not be covered under Medicaid Managed Care/HARP lines of business. Drug coverage will not be available for any product from a non-participating manufacturer. For a complete list of New/Reinstated & Terminated Labelers please visit: <https://www.medicaid.gov/medicaid/prescriptiondrugs/medicaid-drug-rebate-program/newreinstated-terminated-labeler-information/index.html>
11. This policy is based on available evidence as of the last review date. Coverage determinations are subject to applicable plan documents, state and federal regulations, and individual patient circumstances. This policy does not constitute medical advice.
12. For commercial contracts, medical necessity determinations align with the Certificate of Coverage issued by the Health Plan, which states that covered services must be clinically appropriate and not primarily for the convenience of the member, the member's family, or the provider.
13. This policy is subject to ongoing revision. Newly marketed drugs and existing drugs with new indications may be subject to prior authorization until formal coverage criteria are established. Inclusion of a drug in this policy does not guarantee its current availability on the market, as some agents may be discontinued, withdrawn, or otherwise unavailable. As product status changes, drugs may be removed from the policy.
14. The requested site of care may impact approval timeframe and is subject to review.
15. The following applies to all gene and cellular therapies unless otherwise specified within the drug-specific coverage criteria:
 - a. Administration, Retreatment, and Treatment with Additional or Other Gene/Cellular Therapies
 - i. One-Time Administration
 1. Most gene and cellular therapies, whether autologous, allogeneic ("off-the-shelf"), or in vivo gene-transfer therapies, are designed and studied as one-time treatments.
 2. Repeat dosing, reinfusion, or sequential therapy with other gene or cellular products has not been established as safe, effective, or clinically appropriate.
 - ii. Retreatment/Repeat Administration
 1. Retreatment with the same gene or cellular therapy product is considered experimental and investigational because:
 - a. Clinical trials evaluated these therapies as single-administration interventions
 - b. Safety, efficacy, and durability of a second administration have not been established
 - c. Risks of immune activation, insertional mutagenesis, or vector immunity may be increased with repeat dosing
 - iii. Treatment with an Additional or Other Gene/Cellular Therapy
 1. Treatment with an additional or different gene or cellular therapy after prior exposure to any gene or cellular therapy is currently considered experimental and investigational as there is lack of evidence demonstrating the following (a-c):
 - a. Anticipated clinical benefit beyond available standard therapies
 - b. Safety of sequential administration
 - c. Justification for selecting a second gene/cellular intervention after a prior one

Pharmacy Management Drug Policy

Lantidra-(donislecel-jujn)

2. This includes, but is not limited to:
 - a. Switching between CAR-T products (e.g., CD19 → CD19 or CD19 → BCMA)
 - b. Switching between autologous and allogeneic cellular therapies
 - c. Sequential use of CAR-T, TCR-T, NK-cell therapies, or other genetically engineered cell therapies
 - d. Receiving a gene therapy after previous gene or cellular therapy exposure
 - e. Receiving an in vivo gene therapy following any prior vector-based therapy
- iv. Prior Gene/Cell Therapy Exposure
 1. An individual is generally not eligible for additional gene or cellular therapy if they have previously received:
 - a. Any autologous cellular therapy (e.g., CAR-T, TCR-T, TIL),
 - b. Any allogeneic genetically modified cellular therapy,
 - c. Any in vivo gene therapy (e.g., AAV, lentiviral vector)
 - d. Any ex vivo gene-modified cell product
 - e. Are being considered for any other gene or cellular therapy without documented evidence supporting safety and anticipated benefit

CODES:

Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract. CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.

Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

Code Key:

Experimental/Investigational = (E/I),

Not medically necessary/ appropriate = (NMN).

Copyright © 2006 American Medical Association, Chicago, IL

UPDATES:

Date	Revision
06/12/2026	Revised
02/12/2026	P&T Committee Review & Approval
01/01/2026	Revised
11/19/2025	Revised
03/06/2025	Revised
02/06/2025	P&T Committee Review & Approval
12/15/2024	Revised
09/13/2024	Revised
06/20/2024	Revised
05/08/2024	Created and Implemented
02/08/2024	P&T Committee Approval

Pharmacy Management Drug Policy

Lantidra-(donislecel-jujn)

REFERENCES:

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report website. <https://www.cdc.gov/diabetes/data/statistics-report/index.html>. Accessed February 1, 2024.
2. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. *Diabetes Care*. 2024;47(Suppl 1):S20-S42. doi:10.2337/dc24-S002
3. American Diabetes Association Professional Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2024. *Diabetes Care*. 2024;47(Suppl 1):S111-S125. doi:10.2337/dc24-S006
4. Holt RIG, DeVries JH, Hess-Fischl A, et al. The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2021;44(11):2589-2625. doi:10.2337/dci21-0043
5. Lantidra [package insert]. Chicago, IL: CellTrans Inc.; 2023
6. Lantidra. U.S. Food and Drug Administration. August 7, 2023. <https://www.fda.gov/vaccines-blood-biologics/lantidra>. Accessed February 1, 2024.